MNMD
Mind Medicine (MindMed) Inc.
$12.55
-$0.04(-0.32%)
46
Overall
40
Value
66
Tech
34
Quality
Market Cap
$1.17B
Volume
1.18M
52W Range
$4.70 - $14.43
Target Price
$25.64
Company Overview
| Mkt Cap | $1.17B | Price | $12.55 |
| Volume | 1.18M | Change | -0.32% |
| P/E Ratio | -10.8 | Open | $12.94 |
| Revenue | -- | Prev Close | $12.59 |
| Net Income | $-108.7M | 52W Range | $4.70 - $14.43 |
| Div Yield | N/A | Target | $25.64 |
| Overall | 46 | Value | 40 |
| Quality | 34 | Technical | 66 |
No chart data available
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MNMD | $12.55 | -0.3% | 1.18M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Mind Medicine (MindMed) Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW